AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30806520 — intervention group
Group type: EXPERIMENTAL
Intervention: Secukinumab 300 mg
Number of subjects: 0
Study 30806520 — intervention group
Group type: COMPARATOR
Intervention: Infliximab
Number of subjects: 0
Study 28103179 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention message
Number of subjects: 0
Study 28103179 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 23633748 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg mirtazapine nightly for 7 days
Number of subjects: 12
Study 23633748 — intervention group
Group type: COMPARATOR
Intervention: Baseline (drug-free) nights
Number of subjects: 12
Study 23964470 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A (BoNT-A) - 500 units (Dysport) administered via injection
Number of subjects: 384
Study 19032561 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam (1 mg injected i.v. at 30-s intervals until no response to hand grasp test) in Group BS (bilateral spinal anesthesia)
Number of subjects: 42
Study 19032561 — intervention group
Group type: COMPARATOR
Intervention: Midazolam (1 mg injected i.v. at 30-s intervals until no response to hand grasp test) in Group US (unilateral spinal anesthesia)
Number of subjects: 42
Study 17100860 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive educational programme for peer review groups focusing on treatment of chronic heart failure (CHF)
Number of subjects: 160
Study 17100860 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive educational programme for peer review groups focusing on hypertension treatment in diabetes mellitus type 2 (T2DM)
Number of subjects: 160
Study 14675803 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (24 IU) with social support from a best friend
Number of subjects: 37
Study 14675803 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (24 IU) without social support
Number of subjects: 37
Study 14675803 — intervention group
Group type: COMPARATOR
Intervention: Placebo with social support from a best friend
Number of subjects: 37
Study 14675803 — intervention group
Group type: COMPARATOR
Intervention: Placebo without social support
Number of subjects: 37
Study 11016449 — intervention group
Group type: EXPERIMENTAL
Intervention: Adapted cow's milk (CM) formula
Number of subjects: 0
Study 11016449 — intervention group
Group type: COMPARATOR
Intervention: Hydrolyzed casein (HC) formula
Number of subjects: 0
Study 9005381 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral liquid ferrous gluconate (75 mg per diem in 2 vials a day)
Number of subjects: 40
Study 9005381 — intervention group
Group type: COMPARATOR
Intervention: Solid ferrous gluconate (80 mg per diem in a single effervescent tablet)
Number of subjects: 40
Study 9005381 — intervention group
Group type: COMPARATOR
Intervention: Solid ferrous sulphate (105 mg per diem in a single tablet)
Number of subjects: 40
Study 9005381 — intervention group
Group type: COMPARATOR
Intervention: Ferric protein succinylate (80 mg per diem in 2 vials a day)
Number of subjects: 40
Study 1282588 — intervention group
Group type: EXPERIMENTAL
Intervention: Ro 42-5892 (0.1 mg/kg) fast infusion
Number of subjects: 9
Study 1282588 — intervention group
Group type: EXPERIMENTAL
Intervention: Ro 42-5892 (0.1 mg/kg) slow infusion
Number of subjects: 9
Study 1282588 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 3839424 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 CMF cycles
Number of subjects: 0
Study 3839424 — intervention group
Group type: COMPARATOR
Intervention: No postoperative chemotherapy
Number of subjects: 0
Study 3839424 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential non-cross resistant combinations (CMFP-AV) at full dose
Number of subjects: 0
Study 29762731 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.8% of DM SBP (8SBP)
Number of subjects: 41
Study 29762731 — intervention group
Group type: EXPERIMENTAL
Intervention: 16.0% of DM SBP (16SBP)
Number of subjects: 41
Study 29762731 — intervention group
Group type: EXPERIMENTAL
Intervention: 23.5% of DM SBP (24SBP)
Number of subjects: 41
Study 29762731 — intervention group
Group type: COMPARATOR
Intervention: 0% SBP (control)
Number of subjects: 41
Study 26706237 — intervention group
Group type: EXPERIMENTAL
Intervention: Aflibercept plus FOLFIRI
Number of subjects: 1102
Study 26706237 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus FOLFIRI
Number of subjects: 1102
Study 26706237 — intervention group
Group type: EXPERIMENTAL
Intervention: Aflibercept plus FOLFIRI (in bevacizumab-pretreated subgroup)
Number of subjects: 1102
Study 26706237 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus FOLFIRI (in bevacizumab-pretreated subgroup)
Number of subjects: 1102
Study 24507910 — intervention group
Group type: EXPERIMENTAL
Intervention: Loss of social influence in young men working with other young men
Number of subjects: 0
Study 24507910 — intervention group
Group type: COMPARATOR
Intervention: Gain of social influence in young men working with other young men
Number of subjects: 0
Study 24507910 — intervention group
Group type: COMPARATOR
Intervention: Young men working with women
Number of subjects: 0
Study 24507910 — intervention group
Group type: COMPARATOR
Intervention: Women working with other women or men
Number of subjects: 0
Study 22458831 — intervention group
Group type: EXPERIMENTAL
Intervention: Fathers who cut the umbilical cord
Number of subjects: 105
Study 22458831 — intervention group
Group type: COMPARATOR
Intervention: Fathers who did not cut the umbilical cord
Number of subjects: 105
Study 20814323 — intervention group
Group type: EXPERIMENTAL
Intervention: Current exposure to antipsychotic drugs
Number of subjects: 111818
Study 20814323 — intervention group
Group type: EXPERIMENTAL
Intervention: Dosage and duration of antipsychotic drug use
Number of subjects: 111818
Study 20814323 — intervention group
Group type: EXPERIMENTAL
Intervention: Type of antipsychotic drug
Number of subjects: 111818
Study 18072822 — intervention group
Group type: EXPERIMENTAL
Intervention: HEP-40 2,400 mg once daily
Number of subjects: 105
Study 18072822 — intervention group
Group type: EXPERIMENTAL
Intervention: HEP-40 400 mg three times daily
Number of subjects: 105
Study 18072822 — intervention group
Group type: EXPERIMENTAL
Intervention: HEP-40 800 mg three times daily
Number of subjects: 105
Study 18072822 — intervention group
Group type: EXPERIMENTAL
Intervention: HEP-40 800 mg twice daily
Number of subjects: 105
Study 18072822 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 105
Study 15613421 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal testosterone (Intrinsa, 150 mug)
Number of subjects: 33
Study 15613421 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal testosterone (Intrinsa, 300 mug)
Number of subjects: 33
Study 15613421 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal testosterone (Intrinsa, 150 mug or 300 mug)
Number of subjects: 33
Study 15613421 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study 14606376 — intervention group
Group type: EXPERIMENTAL
Intervention: Obese patients with PEEP at 10 cm H2O after recruitment maneuver
Number of subjects: 90
Study 14606376 — intervention group
Group type: EXPERIMENTAL
Intervention: Obese patients with PEEP at 5 cm H2O after recruitment maneuver
Number of subjects: 90
Study 14606376 — intervention group
Group type: COMPARATOR
Intervention: Control group (normal BMI)
Number of subjects: 90
Study 10721156 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipin (5 mg q.d.) with further steps including ACE-inhibitors or beta-blockers, increasing Felodipin dose to 100 mg, and adding diuretics if necessary; also 75 mg acetyl-salicylic acid
Number of subjects: 18790
Study 10721156 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18790
Study 7483305 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized intertrial interval in gap task
Number of subjects: 5
Study 7483305 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized fixation foreperiod in gap task
Number of subjects: 5
Study 7483305 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized fixation foreperiod in overlap task
Number of subjects: 5
Study 7483305 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized gap and overlap trials
Number of subjects: 5
Study 7483305 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized gap durations
Number of subjects: 5
Study 7483305 — intervention group
Group type: COMPARATOR
Intervention: Non-random control sessions
Number of subjects: 5
Study 2407885 — intervention group
Group type: EXPERIMENTAL
Intervention: Cuprophan (CU) dialyzer
Number of subjects: 0
Study 2407885 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemophan (HE) dialyzer
Number of subjects: 0
Study 2407885 — intervention group
Group type: EXPERIMENTAL
Intervention: Polysulfone F6 (PS) dialyzer
Number of subjects: 0
Study 2407885 — intervention group
Group type: EXPERIMENTAL
Intervention: Dialyzers sterilized with ETO
Number of subjects: 0
Study 2407885 — intervention group
Group type: COMPARATOR
Intervention: C3a and C5a
Number of subjects: 0
Study 2407885 — intervention group
Group type: EXPERIMENTAL
Intervention: Flow cytofluorometry and immunohistochemical methods (APAAP)
Number of subjects: 0
Study 2407885 — intervention group
Group type: EXPERIMENTAL
Intervention: C8 dependent generation of PGE2 and TNF alpha by adherent monocytes induced by cuprophan
Number of subjects: 0
Study 6985702 — intervention group
Group type: EXPERIMENTAL
Intervention: Delta-9-tetrahydrocannabinol (THC)
Number of subjects: 25
Study 6985702 — intervention group
Group type: COMPARATOR
Intervention: Prochlorperazine (compazine)
Number of subjects: 25
Study 30726946 — intervention group
Group type: EXPERIMENTAL
Intervention: High dietary insulin load
Number of subjects: 1023
Study 30726946 — intervention group
Group type: EXPERIMENTAL
Intervention: High dietary insulin index
Number of subjects: 1023
Study 30726946 — intervention group
Group type: EXPERIMENTAL
Intervention: High dietary insulin load in patients with obesity
Number of subjects: 1023
Study 28320345 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone follow-up at 8, 30, and 60 days after treatment for attempted suicide
Number of subjects: 436
Study 28320345 — intervention group
Group type: COMPARATOR
Intervention: No telephone follow-up (Control group)
Number of subjects: 436
Study 25555539 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive behavior support (PBS)
Number of subjects: 731
Study 25555539 — intervention group
Group type: COMPARATOR
Intervention: Dietary quality of meals
Number of subjects: 731
Study 25000151 — intervention group
Group type: EXPERIMENTAL
Intervention: Labisia pumila var alata water extract (400 mg)
Number of subjects: 197
Study 23251355 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based tailored lifestyle advice and face-to-face counselling
Number of subjects: 340
Study 23251355 — intervention group
Group type: COMPARATOR
Intervention: Usual care control group
Number of subjects: 340
Study 19300199 — intervention group
Group type: EXPERIMENTAL
Intervention: Steroid withdrawal over 3 months
Number of subjects: 42
Study 19300199 — intervention group
Group type: COMPARATOR
Intervention: Control group (continued steroids)
Number of subjects: 42
Study 19300199 — intervention group
Group type: EXPERIMENTAL
Intervention: Steroid withdrawal
Number of subjects: 42
Study 19300199 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 42
Study 17562632 — intervention group
Group type: EXPERIMENTAL
Intervention: Support group (n = 14)
Number of subjects: 29
Study 17562632 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 15)
Number of subjects: 29
Study 15156427 — intervention group
Group type: EXPERIMENTAL
Intervention: Directly Administered Antiretroviral Therapy (DAART) program, 1 of 2 daily HAART doses, 5 days per week for 6 months
Number of subjects: 67
Study 11472883 — intervention group
Group type: EXPERIMENTAL
Intervention: Levodopa (one 250/50‐mg tablet)
Number of subjects: 38
Study 11472883 — intervention group
Group type: EXPERIMENTAL
Intervention: Biperiden (one 3‐mg tablet)
Number of subjects: 38
Study 11472883 — intervention group
Group type: COMPARATOR
Intervention: Levodopa and Biperiden
Number of subjects: 38
Study 9505256 — intervention group
Group type: EXPERIMENTAL
Intervention: Residual limb
Number of subjects: 16
Study 9505256 — intervention group
Group type: COMPARATOR
Intervention: Contralateral limb
Number of subjects: 16
Study 9505256 — intervention group
Group type: EXPERIMENTAL
Intervention: Age-dependent factors
Number of subjects: 16
Study 9505256 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep pressure sensation
Number of subjects: 16
Study 8001212 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole (20 mg per dose, two doses)
Number of subjects: 104
Study 8001212 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole (two doses)
Number of subjects: 104
Study 8001212 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole (single dose on the morning of surgery)
Number of subjects: 104
Study 8001212 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole-Omeprazole and Omeprazole-Placebo Groups
Number of subjects: 104
Study 8001212 — intervention group
Group type: COMPARATOR
Intervention: Placebo-Placebo and Placebo-Omeprazole Groups
Number of subjects: 104
Study 2123152 — intervention group
Group type: EXPERIMENTAL
Intervention: rt-PA (0.6 mg/kg, 2-minute infusion)
Number of subjects: 58
Study 2123152 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 58
Study 2123152 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 58
Study 363702 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral rapid neuroleptization method (maximum 80 mg/day)
Number of subjects: 32
Study 363702 — intervention group
Group type: COMPARATOR
Intervention: Fixed standard dosage (20 mg/day)
Number of subjects: 32
Study 31447409 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 μg teriparatide + denosumab 60 mg every 6 months
Number of subjects: 76
Study 31447409 — intervention group
Group type: COMPARATOR
Intervention: 20 μg teriparatide + denosumab 60 mg every 6 months
Number of subjects: 76
Study 27299475 — intervention group
Group type: EXPERIMENTAL
Intervention: memantine
Number of subjects: 30
Study 27299475 — intervention group
Group type: COMPARATOR
Intervention: risperidone
Number of subjects: 30
Study 26992609 — intervention group
Group type: EXPERIMENTAL
Intervention: C-reactive protein (CRP)
Number of subjects: 717
Study 26992609 — intervention group
Group type: EXPERIMENTAL
Intervention: Interleukin (IL)-6
Number of subjects: 717
Study 26992609 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline CRP concentration
Number of subjects: 717
Study 26992609 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline IL-6 levels
Number of subjects: 717
Study 26992609 — intervention group
Group type: EXPERIMENTAL
Intervention: Change in biomarker levels during the first month after DVT
Number of subjects: 717
Study 23917905 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound monitoring with audio reminders and written individual feedback
Number of subjects: 106
Study 23917905 — intervention group
Group type: COMPARATOR
Intervention: Control group (manual observations)
Number of subjects: 106
Study 21325465 — intervention group
Group type: EXPERIMENTAL
Intervention: 16 mg phytoestrogens
Number of subjects: 60
Study 21325465 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg phytoestrogens
Number of subjects: 60
Study 19264792 — intervention group
Group type: EXPERIMENTAL
Intervention: CoPAT (Outpatient parenteral antimicrobial therapy)
Number of subjects: 200
Study 19264792 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy (semi‐synthetic penicillin or vancomycin with initial low‐dose gentamicin)
Number of subjects: 200
Study 19264792 — intervention group
Group type: EXPERIMENTAL
Intervention: CoPAT with daptomycin
Number of subjects: 200
Study 19264792 — intervention group
Group type: EXPERIMENTAL
Intervention: CoPAT with standard therapy
Number of subjects: 200
Study 17091660 — intervention group
Group type: EXPERIMENTAL
Intervention: Fuji VII sealant material
Number of subjects: 200
Study 17091660 — intervention group
Group type: COMPARATOR
Intervention: Concise resin-based sealant
Number of subjects: 200
Study 16429657 — intervention group
Group type: EXPERIMENTAL
Intervention: Dutasteride 0.5 mg per day for 4 weeks before operation
Number of subjects: 59
Study 16429657 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study 12726782 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-session group-based exercise intervention for smoking cessation; Exercise instructions began at Session 8 and continued through Session 12
Number of subjects: 91
Study 12726782 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-session group-based exercise intervention for smoking cessation; Exercise commenced at Session 1
Number of subjects: 91
Study 12726782 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined subjects from both studies
Number of subjects: 91
Study 9893087 — intervention group
Group type: EXPERIMENTAL
Intervention: Written materials only
Number of subjects: 1247
Study 9893087 — intervention group
Group type: COMPARATOR
Intervention: Written materials and educational videotape
Number of subjects: 1247
Study 7579025 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine (20 mg)
Number of subjects: 671
Study 7579025 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 671
Study 7579025 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 671
Study 1968319 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg dipotassium chlorazepate (DC)
Number of subjects: 60
Study 1968319 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 6992913 — intervention group
Group type: EXPERIMENTAL
Intervention: Plain catgut subcutaneous fat stitch
Number of subjects: 208
Study 6992913 — intervention group
Group type: COMPARATOR
Intervention: No fat suture
Number of subjects: 208
Study 12381252 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin 40 mg daily
Number of subjects: 9014
Study 29908043 — intervention group
Group type: EXPERIMENTAL
Intervention: PF-06741086 (30 mg subcutaneously to 440 mg intravenously)
Number of subjects: 41
Study 26893507 — intervention group
Group type: EXPERIMENTAL
Intervention: Pilates exercises
Number of subjects: 100
Study 26893507 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized exercises
Number of subjects: 100
Study 26893507 — intervention group
Group type: COMPARATOR
Intervention: Relaxation
Number of subjects: 100
Study 25307141 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-WTG exercise training for participants
Number of subjects: 19
Study 25307141 — intervention group
Group type: COMPARATOR
Intervention: Nonparticipant controls
Number of subjects: 19
Study 22087803 — intervention group
Group type: EXPERIMENTAL
Intervention: Triclosan/copolymer dentifrice
Number of subjects: 30
Study 22087803 — intervention group
Group type: COMPARATOR
Intervention: Placebo dentifrice
Number of subjects: 30
Study 19657665 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyst aspiration (n = 90)
Number of subjects: 180
Study 19657665 — intervention group
Group type: COMPARATOR
Intervention: No-intervention (n = 90)
Number of subjects: 180
Study 18045719 — intervention group
Group type: EXPERIMENTAL
Intervention: Goat milk-derived E2 antigen
Number of subjects: 0
Study 18045719 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 16134998 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypobaric environment (2500 m)
Number of subjects: 20
Study 16134998 — intervention group
Group type: COMPARATOR
Intervention: Normobaric environment (200 m)
Number of subjects: 20
Study 11856987 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled glucocorticosteroids
Number of subjects: 28
Study 11856987 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 10023789 — intervention group
Group type: EXPERIMENTAL
Intervention: Breathe Right (BR) strip
Number of subjects: 54
Study 10023789 — intervention group
Group type: EXPERIMENTAL
Intervention: Xylometazoline
Number of subjects: 54
Study 10023789 — intervention group
Group type: COMPARATOR
Intervention: Nasal baseline maneuver
Number of subjects: 54
Study 10023789 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal maneuver after application of xylometazoline
Number of subjects: 54
Study 7775644 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg/day finasteride
Number of subjects: 20
Study 7775644 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 2157231 — intervention group
Group type: EXPERIMENTAL
Intervention: Gepirone 10 mg
Number of subjects: 12
Study 2157231 — intervention group
Group type: EXPERIMENTAL
Intervention: Gepirone 20 mg
Number of subjects: 12
Study 2157231 — intervention group
Group type: EXPERIMENTAL
Intervention: Gepirone (both dosages)
Number of subjects: 12
Study 6765467 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin 0.2 mg/kg
Number of subjects: 23
Study 6765467 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 30913943 — intervention group
Group type: EXPERIMENTAL
Intervention: TENS combined with traditional physical therapy
Number of subjects: 29
Study 30913943 — intervention group
Group type: COMPARATOR
Intervention: Traditional physical therapy (Control)
Number of subjects: 29
Study 28321022 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor (90 mg twice-daily)
Number of subjects: 40
Study 28321022 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel (150 mg once-daily)
Number of subjects: 40
Study 28321022 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 40
Study 28321022 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 40
Study 28321022 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 40
Study 26156114 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 Hz stimulation of the sensory vagal area at the left ear for 4 h/day during 3 months
Number of subjects: 46
Study 26156114 — intervention group
Group type: COMPARATOR
Intervention: 25 Hz stimulation of the sensory vagal area at the left ear for 4 h/day during 3 months
Number of subjects: 46
Study 26156114 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (1 Hz and 25 Hz)
Number of subjects: 46
Study 23303149 — intervention group
Group type: EXPERIMENTAL
Intervention: Pursestring closure
Number of subjects: 61
Study 23303149 — intervention group
Group type: COMPARATOR
Intervention: Linear closure (Control)
Number of subjects: 61
Study 21134027 — intervention group
Group type: EXPERIMENTAL
Intervention: Biventricular pacing (CRT)
Number of subjects: 40